

Rapid, Quality Results. No Compromise.





Xpert® **Xpress** Strep A



To accurately diagnose pharyngitis caused by Group A Streptococcus (GAS) due to increasing incidence and prevalence globally.

 Annually, 616 million people have GAS pharyngitis, more than 18.1 million people develop severe GAS disease and more than 517,000 people die due to severe GAS disease.¹

Reduce overuse of antibiotics for the treatment of pharyngitis.

Based on recent literature 37% of children presenting with pharyngitis tested positive for GAS, however 56% of visits were associated with antibiotic prescriptions. Similarly, 18% of adults presenting with pharyngitis caused by GAS, but 72% were treated with antibiotics.²



The Solution

- Cepheid provides on-demand testing for Group A Strep in as soon as 18 minutes*
- Careful selection of the target gene produces quality results
- Delivering accurate and timely results optimizes fast treatment decisions



The Impact

- Accurate diagnosis of GAS supports antimicrobial stewardship and may reduce the amount of patients inappropriately prescribed antibiotics.
- Gain testing efficiencies and reduce costs by eliminating culture confirmation testing.³
- Reduce the risk of GAS complications such as rheumatic fever and glomerulonephritis.
- Improve patient satisfaction with quicker time to result and appropriate prescriptions.

That's the **PCR***plus* advantage. From Cepheid.


Guidelines recommend antibiotic treatment for all suspected group A Streptococcus (GAS) infections.²"

The Infectious Disease Society of America further clarifies that, with the rare exception of infection by certain *Corynebacterium diphtheriae* and *Neisseria gonorrhoeae*, antimicrobial therapy is of no proven benefit as treatment for acute pharyngitis due to organisms other than Group A Streptococcus.⁴

Impact on Outpatient Pathway

Improving Patient Satisfaction

Xpert **Xpress** Strep A provides medically actionable and timely information to clinicians to support improved patient management and antibiotic stewardship.



^{*} With Early Assay Termination (EAT) for positive results. Refer to Package Insert Xpert Xpress Strep A CE-IVD 301-6569.



		CATALOG INFORMATION
Xpert® Xpress Strep A	10 tests	XPRSTREPA-CE-10
COLLECTION DEVICES (NOT INCLUDED IN KIT)		CATALOG INFORMATION
Copan E-Swab in Liquid Amies	50 test kits	480CE and 480C

CE-IVD. In Vitro Diagnostic Medical Device. Not available in all countries.

* With Early Assay Termination (EAT) for positive results. Refer to Package Insert Xpert Xpress Strep A CE-IVD 301-6569.

References:

- 1 The Global Burden of Group A Streptococcal Diseases. Lancet Infect Dis. 2005 Nov; 5(11):685-94.
- 2 Ralph AP et al. Potential for Molecular Testing for Group A Streptococcus to Improve Diagnosis and Management in a High-Risk Population: A Prospective Study. Open Forum Infect Dis. 2019 Feb 26;6(4):ofz097.
- 3 Workflow studies conducted by Cepheid Solutions demonstrate that a throat culture confirmation workup costs~\$9.13 per culture. (Average cost includes reagents, labor cost and time). Data on file.
- 4 Shulman ST, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2012 Nov 15;55(10):1279-82.

CORPORATE HEADQUARTERS

904 Caribbean Drive Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743
PHONE +1.408.541.4191
FAX +1.408.541.4192

EUROPEAN HEADQUARTERS

www. Cepheid in ternation al. com

Vira Solelh 81470 Maurens-Scopont France PHONE +33.563.82.53.00 FAX +33.563.82.53.01

+33.563.82.53.01 cepheid@cepheideurope.fr © 2023–2024 Cepheid. 3106-03

